MedPath

MYELOID THERAPEUTICS

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)โ€ข Click on a phase to view related trials

Phase 1
3 (100.0%)

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Phase 1
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2024-06-27
Last Posted Date
2025-02-04
Lead Sponsor
Myeloid Therapeutics
Target Recruit Count
48
Registration Number
NCT06478693
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

St Vincent's Hospital, Sydney, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba, Queensland, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

The Alfred Hospital, Melbourne, Victoria, Australia

and more 4 locations

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Phase 1
Recruiting
Conditions
Epithelial Tumors, Malignant
Interventions
Drug: MT-302 (A)
First Posted Date
2023-08-01
Last Posted Date
2024-01-18
Lead Sponsor
Myeloid Therapeutics
Target Recruit Count
48
Registration Number
NCT05969041
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Scientia Clinical Research Ltd, Randwick, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Westmead Hospital, Westmead, New South Wales, Australia

and more 3 locations

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Phase 1
Suspended
Conditions
Lymphoma, T-Cell, Peripheral
Mycosis Fungoides
Cell Therapy
Lymphoma, T-Cell, Cutaneous
Adoptive Cellular Immunotherapy
First Posted Date
2021-12-01
Last Posted Date
2023-11-13
Lead Sponsor
Myeloid Therapeutics
Target Recruit Count
40
Registration Number
NCT05138458
Locations
๐Ÿ‡บ๐Ÿ‡ธ

City of Hope Comprehensive Cancer Center, Duarte, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Colorado Blood Cancer Institute, Denver, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Mass General Brigham Cancer Care, Boston, Massachusetts, United States

and more 3 locations

News

Myeloid Therapeutics Reports First-in-Human Data for In Vivo mRNA CAR Therapies at ASCO 2025

Myeloid Therapeutics presented first-in-human data for MT-302 and MT-303, marking the first clinical applications of systemically administered in vivo mRNA CAR therapies.

Myeloid Therapeutics' MT-303, a Novel mRNA CAR Therapy, Enters Phase 1 Trial for Liver Cancer

MT-303, a GPC3-targeting CAR mRNA therapy, is being evaluated in a Phase 1 trial (NCT06478693) for advanced hepatocellular carcinoma (HCC).

In Vivo CAR T-Cell Therapies Advance to Clinical Trials, Promising Faster, Cheaper Cancer Treatment

In vivo CAR T-cell generation uses off-the-shelf reprogramming cassettes, potentially reducing manufacturing time and costs compared to ex vivo CAR Ts.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.